An open-label, prospective, comparative trial to assess prostate specific antigen progression on bicalutamide monotherapy versus bicalutamide and dutasteride therapy in patients with advanced and/or metastatic carcinoma of the prostate.

Trial Profile

An open-label, prospective, comparative trial to assess prostate specific antigen progression on bicalutamide monotherapy versus bicalutamide and dutasteride therapy in patients with advanced and/or metastatic carcinoma of the prostate.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2012

At a glance

  • Drugs Bicalutamide (Primary) ; Dutasteride (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms AVOCAT
  • Most Recent Events

    • 01 Apr 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 05 Feb 2009 Last checked against Netherlands Trial Register record.
    • 05 Feb 2009 Status changed from not stated to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top